Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pasithea Therapeutics (KTTA) Long-Term Debt Issuances (2021 - 2023)

Pasithea Therapeutics recorded quarterly Long-Term Debt Issuances of $392354.0 in Q1 2023, down 92.6% quarter-over-quarter from $5.3 million in Q4 2021.

Pasithea Therapeutics' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at $392354.0 for Q1 2023.

  • In Q1 2023, Long-Term Debt Issuances changed N/A year-over-year to $392354.0; the TTM figure through Dec 2023 stood at $392354.0 (changed N/A YoY), while the FY2023 annual figure was $392354.0, changed N/A from the prior year.
  • Long-Term Debt Issuances came in at $392354.0 for Q1 2023 at Pasithea Therapeutics, down from $5.3 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $20.7 million in Q3 2021 to a low of $392354.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 2.73 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Pasithea Therapeutics 17.41 Mn 17.41 Mn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2023 392,354.00
Mar 31, 2023 392,354.00
Dec 31, 2021 5.30 Mn
Dec 31, 2021 5.30 Mn
Sep 30, 2021 20.65 Mn
Sep 30, 2021 20.65 Mn
Mar 31, 2021 1.21 Mn
Mar 31, 2021 1.21 Mn